Prediction of trifluridine/tipiracil (TAS-102) effectiveness in patients with refractory metastatic colorectal cancer (mCRC): Real-life data from the Czech Republic.

被引：0
|
作者：
Grell, Peter
Dvorak, Josef
Vocka, Michal
John, Stanislav
Tuskova, Helena
Buchler, Tomas
Borilova, Simona
Selingerova, Iveta
Vyzula, Rostislav
Petruzelka, Lubos B.
Kiss, Igor
Obermannova, Radka
机构：
[1] Masaryk Mem Canc Inst, Brno, Czech Republic
[2] Charles Univ Med Sch & Teaching Hosp, Hradec Kralove, Czech Republic
[3] Charles Univ Prague, Prague, Czech Republic
[4] Dept Oncol & Radiotherapy, Hradec Kralove, Czech Republic
[5] Charles Univ Prague, Fac Med 1, Dept Oncol, Prague, Czech Republic
[6] Thomayer Univ Hosp, Prague, Czech Republic
[7] Masaryk Mem Canc Inst, Reg Ctr Appl Mol Oncol, Brno, Czech Republic
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e15102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15102
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Utilization of TAS-102 (TAS) or regorefenib (Rego) among commercially insured refractory metastatic colorectal cancer (R-mCRC) patients.
    Zheng, Hanke
    Yu, Tianzhou
    Romley, John
    Barzi, Afsaneh
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [42] TAGS: A phase III, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer
    Arkenau, H-T.
    Tabernero, J.
    Shitara, K.
    Dvorkin, M.
    Mansoor, W.
    Prokharau, A.
    Alsina, M.
    Ghidini, M.
    Faustino, C.
    Gorbunova, V.
    Zhavrid, E. A.
    Nishikawa, K.
    Hosokawa, A.
    Ganea, D.
    Yalcin, S.
    Beretta, G. D.
    Winkler, R. E.
    Makris, L.
    Doi, T.
    Ilson, D. H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [43] TAS-102 in patients with metastatic colorectal cancer refractory to standard therapies including regorafenib
    Kito, Yosuke
    Hamauchi, Satoshi
    Yamazaki, Kentaro
    Komori, Azusa
    Masuishi, Toshiki
    Taniguchi, Hiroya
    Mori, Keita
    Muro, Kei
    Yasui, Hirofumi
    ANNALS OF ONCOLOGY, 2016, 27
  • [44] Therapeutic effect of TAS-102 (A) in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy by the Kohne model (Km).
    Nishina, Tomohiro
    Yoshino, Takayuki
    Mizunuma, Nobuyuki
    Yamazaki, Kentaro
    Komatsu, Yoshito
    Baba, Hideo
    Tsuji, Akihito
    Yamaguchi, Kensei
    Muro, Kei
    Ohtsu, Atsushi
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [45] Regorafenib-to-trifluridine/tipiracil Versus the Reverse Sequence for Refractory Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Real-life Experience
    Signorelli, Carlo
    Gemma, Donatello
    Grande, Roberta
    De Marco, Salvatore
    Saltarelli, Rosa
    Morandi, Maria Grazia
    Spinelli, Gian Paolo
    Zoratto, Federica
    Sperduti, Isabella
    Chilelli, Mario Giovanni
    Ceribelli, Anna
    Ruggeri, Enzo Maria
    ANTICANCER RESEARCH, 2021, 41 (05) : 2553 - 2561
  • [46] Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer
    Zhang, Jing
    Yang, Wenwei
    Liu, Junbao
    Wang, Nan
    Ren, Zhaoying
    Yang, Tingting
    Xie, Gongli
    Wu, Guifu
    Sun, Yongkun
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (04) : 454 - 461
  • [47] Factors associated with effectiveness of trifluridine/tipiracil versus regorafenib in patients with pretreated metastatic colorectal cancer (mCRC)
    Grell, Peter
    Borilova, Simona
    Schwanzerova, Renata
    Kukolikova, Sabina
    Dvorak, Josef
    Vocka, Michal
    John, Stanislav
    Buchler, Tomas
    Selingerova, Iveta
    Petruzelka, Lubos B.
    Vyzula, Rostislav
    Kiss, Igor
    Obermannova, Radka
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [48] The international open-label early-access study of trifluridine/tipiracil (TAS-102) in patients with pretreated metastatic colorectal cancer (phase IIIb)
    Alfredo, Falcone
    Jean-Francois, Seitz
    Timothy, Price
    Lucjan, Wyrwicz
    Alice, Dorbon
    Natividad, Lopez Busto
    Nadjat, Mounedji
    Eric, Van Cutsem
    ANNALS OF ONCOLOGY, 2017, 28
  • [49] Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer under oral trifluridine-tipiracil (TAS-102) chemotherapy
    Kimura, M.
    Usami, E.
    Iwai, M.
    Teramachi, H.
    Yoshimura, T.
    PHARMAZIE, 2017, 72 (01): : 49 - 52
  • [50] Phase I multicenter, open-label study to establish the maximum tolerated dose (MTD) of trifluridine/tipiracil (TAS-102) and oxaliplatin combination in patients (pts) with metastatic colorectal cancer (mCRC)
    Hollebecque, Antoine
    Calvo, Aitana
    Andre, Thierry
    Argiles, Guillem
    Cervantes, Andres
    Leger, Catherine
    Valette, Aude
    Amellal, Nadia
    Fougeray, Ronan
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345